ClinicalTrials.gg
CompletedNCT00942175Updated Feb 3, 2012Results posted

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

A Phase 1 interventional study of Clopidogrel and Clopidogrel and Lansoprazole in Healthy, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-03.

Sponsored by Takeda · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Stomach Ulcer by Takeda — none open to participants now, none under way, none of them phase 3. Stomach Ulcer · Takeda.

Enrollment
10th of 12
160 · median 423
Started
2009
the only one that year
Phase 1
Only one
of the 14
Registered
4th of 14
by date

Among the 14 studies in Stomach Ulcer by Takeda, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2009, is the only one in phase 1, and was the 4th registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

None of the 14 studies in Stomach Ulcer by Takeda is open now. The open studies under Stomach Ulcer, anywhere →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Stomach Ulcer by Takeda as a file.
02

Study summary

The purpose of this study is to assess the potential effect and safety of multiple oral doses of dexlansoprazole, lansoprazole, omeprazole or esomeprazole, once daily (QD), on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel, and to assess the safety of multiple doses of clopidogrel in healthy participants.

Read the detailed description

This is a Phase 1, randomized, open-label, single-center, multiple-dose, 2-period, crossover study to assess the effects of multiple oral doses of dexlansoprazole, lansoprazole, omeprazole or esomeprazole on the steady-state pharmacokinetics (PK) and pharmacodynamics (PD) of clopidogrel in healthy participants.

Participants were randomized equally into eight regimen sequence groups, 20 participants each. Participants randomized to Sequence Groups 1 and 2, 3 and 4, 5 and 6 and 7 and 8 were called proton pump inhibitor (PPI) Groups 1, 2, 3, and 4, respectively. Each sequence group consists of 2 regimens. Sequence Groups 1, 3, 5 and 7 dosed Regimen A (75 mg clopidogrel) for Days 1-9 of Period 1 and then crossed over to one of the following 4 regimens for Days 1-9 of Period 2: Regimen B (75 mg clopidogrel + 30 mg lansoprazole), Regimen C (75 mg clopidogrel + 60 mg dexlansoprazole), Regimen D (75 mg clopidogrel + 80 mg [2x40 mg] omeprazole), or Regimen E (75 mg clopidogrel + 40 mg esomeprazole). Sequence Groups 2, 4, 6 and 8 began with either Regimen B, C, D or E for Period 1 and then crossed over to Regimen A for Period 2.

On Day 9 of each period, blood samples were collected at predose and for 24 hours postdose to measure plasma concentrations of the active metabolite of clopidogrel. Platelet function was assessed daily prior to the dose of clopidogrel on Days 7-9 and 24-hours post Day 9 dose in each period. There was a washout interval of 10 to 14 days between the last dose of study drug in Period 1 and the first dose of study drug in Period 2.

Study participants were confined to the study center for 10 consecutive nights in Period 1, followed by a 10- to 14-day washout interval and confined for an additional 10 consecutive nights in Period 2.

03

Conditions studied

  • Healthy

Keywords

  • Pharmacology
  • Stomach Ulcer
  • Esophagitis, Peptic
  • Zollinger-Ellison Syndrome
  • Platelet function
  • PPI
  • clopidogrel
  • Pharmacokinetics and Pharmacodynamics
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant or the participant's legally acceptable representative signs a written, form prior to the initiation of any study procedures.
  2. Weighs at least 50 kg and has a (BMI) between 18 and 30 kg/m2, inclusive, at Screening and Check-in (Day -1 of Period 1) Visits.
  3. Must be a CYP2C19 extensive metabolizer (wt/wt).
  4. Females cannot be nursing and must have a negative urine pregnancy test at Day -1 or be of non-. If females are of child bearing potential, must have a negative serum human chorionic gonadotropin (hCG) pregnancy test during Screening and on an acceptable form of , or have had bilateral tubal ligation if performed a minimum of 90 days prior to Day 1.
  5. At the Screening and Check-in (Day -1 of Period 1) Visits, must have an estimated (CLcr) greater than or equal 90 mL/minute as determined from the Cockcroft-Gault formula.
  6. Is in good health as determined by a physician based upon medical history, , and physical examination findings at the Screening and Check-in (Day -1 of Period 1) Visits.
  7. Participant's clinical laboratory evaluations (including hematology, clinical chemistry [fasted for a least 8 hours], and urinalysis) at the Screening and Check-in (Day -1 of Period 1) Visits are within the reference range for the testing laboratory or are deemed not by the investigator and TGRD Medical Monitor.
  8. Participant's urine drug screen for selected substances of abuse is negative at the Screening and Check-in (Day -1 of Period 1) Visits.

Exclusion criteria

Exclusion Criteria:

  1. Has consumed products containing Seville oranges (sour), grapefruit or grapefruit juice within 14 days prior to the first dose of study drug or is unwilling to agree to abstain from products containing Seville oranges (sour), grapefruit or grapefruit juice while participating in the study.
  2. Has current or recent (within 6 months) gastrointestinal disease, a history of malabsorption, esophageal reflux, gastric bleeding or peptic ulcer disease, frequent (more than once per week) occurrence of heartburn, or any surgical intervention (eg, cholecystectomy), which would be expected to influence the absorption of drugs.
  3. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as the consumption of more than 4 alcoholic beverages per day) within 1 year prior to the Screening Visit or is unwilling to agree to abstain from alcohol and drugs throughout the study.
  4. Is currently participating in another study or has received any investigational compound within 30 days prior to the Check-in (Day -1 of Period 1) Visit.
  5. Has received any known hepatic or renal clearance altering agents (eg, erythromycin, cimetidine, barbiturates, phenothiazines, fluvoxamine, etc.) within 28 days prior to first dose of study drug.
  6. Has a history or clinical manifestations of significant metabolic, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urologic, immunologic, or psychiatric disorder as determined by the investigator which may impact the ability of the participant to take part in or potentially confound the trial results.
  7. Has a history of or allergies to any drug or food or any of clopidogrel, lansoprazole, dexlansoprazole, omeprazole, esomeprazole or other drug with the same mechanism of action or related compounds.
  8. Has had an acute, illness within 30 days prior to the first dose of study drug.
  9. Has a systolic blood pressure greater than 140 mm Hg or has a diastolic blood pressure greater than 90 mm Hg at Screening or Check-in (Day -1 of Period 1).
  10. Has a positive test result for surface antigen (HBsAg) or antibody to virus (anti-HCV) at Screening, or a known history of infection with the (HIV).
  11. Has a Day -1 laboratory value assessed by the principal investigator and sponsor medical monitor as clinically significant underlying disease or condition that may prevent the participant from entering the study.
  12. Has an , aspartate aminotransferase or Total level that exceeds the at the Screening or Check-in (Day -1 of Period 1) Visits.
  13. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 6 weeks prior to Check-in (Day -1 of Period 1) Visit, or has a positive cotinine screen at the Screening or Check-in (Day - 1 of Period 1) Visits or anticipates an inability to abstain from these products for the duration of the study.
  14. With the exception of acetaminophen, has taken any excluded medication, supplements or food products listed in the Excluded Dietary Items and Medications table located in the study protocol.
  15. Has donated blood products (such as plasma) within 30 days, or has donated whole blood or had a significant blood loss (500 mL) within 56 days of the first dose of study drug
  16. Has a positive test result for caffeine at the Check-in (Day -1 of Period 1) Visit.
  17. Has a history of cancer, except basal cell carcinoma, which has not been in remission for at least 5 years prior to the first dose of study drug.
  18. Has received clopidogrel or any PPIs or histamine2-receptor antagonists within 28 days of screening.
  19. Participant, in the opinion of the investigator, is unlikely to comply with the protocol or is unsuitable for any other reason.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Other
    Regimen A

    Clopidogrel 75 mg QD

    Drug: Clopidogrel

  • Other
    Regimen B

    Clopidogrel 75 mg QD and Lansoprazole 30 mg QD

    Drug: Clopidogrel and Lansoprazole

  • Other
    Regimen C

    Clopidogrel 75 mg QD and Dexlansoprazole 60 mg QD

    Drug: Clopidogrel and Dexlansoprazole

  • Other
    Regimen D

    Clopidogrel 75 mg QD and Omeprazole 80 mg QD

    Drug: Clopidogrel and Omeprazole

  • Other
    Regimen E

    Clopidogrel 75 mg QD and Esomeprazole 40 mg QD

    Drug: Clopidogrel and Esomeprazole

Interventions

  • Clopidogrel 75 mg, tablets, orally, once daily days 1-9.

    Also known as: Plavix

  • DrugClopidogrel and Lansoprazole

    Drug pages: Clopidogrel · Lansoprazole

    Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.

    Also known as: Plavix, Prevacid, AG-1749

  • DrugClopidogrel and Dexlansoprazole

    Drug pages: Clopidogrel · Dexlansoprazole

    Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.

    Also known as: Plavix, Kapidex, TAK-390MR

  • DrugClopidogrel and Omeprazole

    Drug pages: Clopidogrel · Omeprazole

    Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.

    Also known as: Plavix

  • DrugClopidogrel and Esomeprazole

    Drug pages: Clopidogrel · Esomeprazole

    Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.

    Also known as: Plavix, Nexium

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite.

    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

    Time frame: Day 9 of each period

  2. Pharmacokinetic Parameter Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]) of Clopidogrel's Active Metabolite.

    Area under the plasma concentration versus time curve (AUC(0-tlqc)) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).

    Time frame: Day 9 of each period

  3. Pharmacodynamic Parameter Platelet Reactivity Index (PRI) From Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation State (Flow Cytometry).

    PRI is the platelet reactivity index from VASP phosphorylation state (flow cytometry).

    Time frame: 24-hour post Day 9 dose in each period.

  4. Pharmacodynamic Parameter Maximum Platelet Aggregation (MPA) From Aggregometry (Turbidimetric) With 5 µM Adenosine Diphosphate.

    Maximum platelet aggregation (MPA) from aggregometry (turbidimetric) with 5 µM adenosine diphosphate.

    Time frame: 24-hour post Day 9 dose in each period.

  5. Pharmacodynamic Parameter MPA From Aggregometry (Turbidimetric) With 20 µM Adenosine Diphosphate.

    MPA from aggregometry (turbidimetric) with 20 µM adenosine diphosphate.

    Time frame: 24-hour post Day 9 dose in each period.

07

Results

Posted Sep 7, 2011

Participant flow

Participants enrolled at one site in the United States from 15 December 2009 to 08 July 2010.

Participant flow — Overall Study
MilestonePPI Group 1PPI Group 2PPI Group 3PPI Group 4
Started40404040
Completed38363838
Not completed2422
Withdrew: Adverse event2100
Withdrew: Protocol violation0120
Withdrew: Pregnancy0001
Withdrew: Elevated alanine amino transferase0001
Withdrew: Low platelet count0200

Outcome measures

PrimaryPharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite.

Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Time frame:
Day 9 of each period
Reported as:
Mean · ng/mL
Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite.
ng/mLPPI Group 1: Regimen APPI Group 1: Regimen BPPI Group 2: Regimen APPI Group 2: Regimen CPPI Group 3: Regimen APPI Group 3: Regimen DPPI Group 4: Regimen APPI Group 4: Regimen E
Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite.39.14 ± 12.55330.01 ± 15.26438.85 ± 15.69929.33 ± 12.40038.25 ± 12.46122.55 ± 10.68240.98 ± 22.90824.69 ± 10.641
Statistical analysis
  • PPI Group 1: Regimen A vs PPI Group 1: Regimen B · Mean difference (final values): 0.7000 · 90% CI 0.6106 to 0.8026The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.
  • PPI Group 2: Regimen A vs PPI Group 2: Regimen C · Mean difference (final values): 0.7340 · 90% CI 0.6516 to 0.8269The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.
  • PPI Group 3: Regimen A vs PPI Group 3: Regimen D · Mean difference (final values): 0.5564 · 90% CI 0.4877 to 0.6347The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.
  • PPI Group 4: Regimen A vs PPI Group 4: Regimen E · Mean difference (final values): 0.6783 · 90% CI 0.5063 to 0.9087The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.
PrimaryPharmacokinetic Parameter Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]) of Clopidogrel's Active Metabolite.

Area under the plasma concentration versus time curve (AUC(0-tlqc)) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).

Time frame:
Day 9 of each period
Reported as:
Mean · ng*hr/ML
Pharmacokinetic Parameter Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]) of Clopidogrel's Active Metabolite.
ng*hr/MLPPI Group 1: Regimen APPI Group 1: Regimen BPPI Group 2: Regimen APPI Group 2: Regimen CPPI Group 3: Regimen APPI Group 3: Regimen DPPI Group 4: Regimen APPI Group 4: Regimen E
Pharmacokinetic Parameter Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]) of Clopidogrel's Active Metabolite.41.69 ± 10.02036.42 ± 10.82541.25 ± 14.69037.75 ± 13.13237.78 ± 12.04326.28 ± 8.80042.35 ± 18.78531.23 ± 9.938
Statistical analysis
  • PPI Group 1: Regimen A vs PPI Group 1: Regimen B · Mean difference (final values): 0.8573 · 90% CI 0.8020 to 0.9165The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.
  • PPI Group 2: Regimen A vs PPI Group 2: Regimen C · Mean difference (final values): 0.9103 · 90% CI 0.8567 to 0.9672The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.
  • PPI Group 3: Regimen A vs PPI Group 3: Regimen D · Mean difference (final values): 0.6943 · 90% CI 0.6438 to 0.7487The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.
  • PPI Group 4: Regimen A vs PPI Group 4: Regimen E · Mean difference (final values): 0.8389 · 90% CI 0.6440 to 1.0928The mean difference refers to the point estimates of the relative bioavailability. With its confidence intervals, it was obtained from the ANOVA model on the natural logarithm transformed data.
PrimaryPharmacodynamic Parameter Platelet Reactivity Index (PRI) From Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation State (Flow Cytometry).

PRI is the platelet reactivity index from VASP phosphorylation state (flow cytometry).

Time frame:
24-hour post Day 9 dose in each period.
Reported as:
Mean · percent inhibition
Pharmacodynamic Parameter Platelet Reactivity Index (PRI) From Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation State (Flow Cytometry).
percent inhibitionPPI Group 1: Regimen APPI Group 1: Regimen BPPI Group 2: Regimen APPI Group 2: Regimen CPPI Group 3: Regimen APPI Group 3: Regimen DPPI Group 4: Regimen APPI Group 4: Regimen E
Pharmacodynamic Parameter Platelet Reactivity Index (PRI) From Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation State (Flow Cytometry).42.3 ± 14.6146.4 ± 16.4441.3 ± 15.4543.0 ± 16.4747.9 ± 15.7059.1 ± 17.8746.5 ± 17.2858.0 ± 14.64
Statistical analysis
  • PPI Group 1: Regimen A vs PPI Group 1: Regimen B · Mean difference (final values): 4.1016 · 90% CI 0.0348 to 8.1684Included only participants with complete data for both regimens. Values are least squares mean difference.
  • PPI Group 2: Regimen A vs PPI Group 2: Regimen C · Mean difference (final values): 2.0474 · 90% CI -0.8555 to 4.9503Included only participants with complete data for both regimens. Values are least squares mean difference.
  • PPI Group 3: Regimen A vs PPI Group 3: Regimen D · Mean difference (final values): 11.0407 · 90% CI 6.5219 to 15.5595Included only participants with complete data for both regimens. Values are least squares mean difference.
  • PPI Group 4: Regimen A vs PPI Group 4: Regimen E · Mean difference (final values): 11.4437 · 90% CI 7.1791 to 15.7083Included only participants with complete data for both regimens. Values are least squares mean difference.
PrimaryPharmacodynamic Parameter Maximum Platelet Aggregation (MPA) From Aggregometry (Turbidimetric) With 5 µM Adenosine Diphosphate.

Maximum platelet aggregation (MPA) from aggregometry (turbidimetric) with 5 µM adenosine diphosphate.

Time frame:
24-hour post Day 9 dose in each period.
Reported as:
Mean · percentage of MPA
Pharmacodynamic Parameter Maximum Platelet Aggregation (MPA) From Aggregometry (Turbidimetric) With 5 µM Adenosine Diphosphate.
percentage of MPAPPI Group 1: Regimen APPI Group 1: Regimen BPPI Group 2: Regimen APPI Group 2: Regimen CPPI Group 3: Regimen APPI Group 3: Regimen DPPI Group 4: Regimen APPI Group 4: Regimen E
Pharmacodynamic Parameter Maximum Platelet Aggregation (MPA) From Aggregometry (Turbidimetric) With 5 µM Adenosine Diphosphate.28.1 ± 6.7630.8 ± 9.3534.6 ± 14.2336.2 ± 16.8734.2 ± 12.3242.5 ± 14.7429.3 ± 10.4138.2 ± 17.77
Statistical analysis
  • PPI Group 1: Regimen A vs PPI Group 1: Regimen B · ANOVA · p = 0.035 (From ANOVA models in which the least-square means between two regimens are compared.)
  • PPI Group 2: Regimen A vs PPI Group 2: Regimen C · ANOVA · p = 0.445 (From ANOVA models in which the least-square means between two regimens are compared.)
  • PPI Group 3: Regimen A vs PPI Group 3: Regimen D · ANOVA · p = <0.001 (From ANOVA models in which the least-square means between two regimens are compared.)
  • PPI Group 4: Regimen A vs PPI Group 4: Regimen E · ANOVA · p = <0.001 (From ANOVA models in which the least-square means between two regimens are compared.)
PrimaryPharmacodynamic Parameter MPA From Aggregometry (Turbidimetric) With 20 µM Adenosine Diphosphate.

MPA from aggregometry (turbidimetric) with 20 µM adenosine diphosphate.

Time frame:
24-hour post Day 9 dose in each period.
Reported as:
Mean · percentage of MPA
Pharmacodynamic Parameter MPA From Aggregometry (Turbidimetric) With 20 µM Adenosine Diphosphate.
percentage of MPAPPI Group 1: Regimen APPI Group 1: Regimen BPPI Group 2: Regimen APPI Group 2: Regimen CPPI Group 3: Regimen APPI Group 3: Regimen DPPI Group 4: Regimen APPI Group 4: Regimen E
Pharmacodynamic Parameter MPA From Aggregometry (Turbidimetric) With 20 µM Adenosine Diphosphate.36.7 ± 9.1141.6 ± 12.6543.1 ± 13.2446.3 ± 16.9343.5 ± 14.0053.5 ± 13.7539.3 ± 13.2247.9 ± 15.77
Statistical analysis
  • PPI Group 1: Regimen A vs PPI Group 1: Regimen B · ANOVA · p = 0.004 (From ANOVA models in which the least-square means between two regimens are compared.)
  • PPI Group 2: Regimen A vs PPI Group 2: Regimen C · ANOVA · p = 0.148 (From ANOVA models in which the least-square means between two regimens are compared.)
  • PPI Group 3: Regimen A vs PPI Group 3: Regimen D · ANOVA · p = <0.001 (From ANOVA models in which the least-square means between two regimens are compared.)
  • PPI Group 4: Regimen A vs PPI Group 4: Regimen E · ANOVA · p = <.0001 (From ANOVA models in which the least-square means between two regimens are compared.)

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started or worsened after the first dose of study drug and within 30 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PPI Group 1: Regimen A—0/40 (0%)13/39 (33.3%)
PPI Group 1: Regimen B—0/40 (0%)16/39 (41%)
PPI Group 2: Regimen A—0/40 (0%)19/39 (48.7%)
PPI Group 2: Regimen C—1/40 (2.5%)16/38 (42.1%)
PPI Group 3: Regimen A—0/40 (0%)14/40 (35%)
PPI Group 3: Regimen D—0/40 (0%)11/38 (28.9%)
PPI Group 4: Regimen A—0/40 (0%)17/39 (43.6%)
PPI Group 4: Regimen E—0/40 (0%)15/39 (38.5%)
Most frequent serious events
Most frequent serious events
EventPPI Group 1: Regimen APPI Group 1: Regimen BPPI Group 2: Regimen APPI Group 2: Regimen CPPI Group 3: Regimen APPI Group 3: Regimen DPPI Group 4: Regimen APPI Group 4: Regimen E
Serum sickness-like reactionInvestigations0/400/400/401/400/400/400/400/40
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPPI Group 1: Regimen APPI Group 1: Regimen BPPI Group 2: Regimen APPI Group 2: Regimen CPPI Group 3: Regimen APPI Group 3: Regimen DPPI Group 4: Regimen APPI Group 4: Regimen E
HeadacheNervous system disorders3/394/395/397/382/406/386/394/39
NauseaGastrointestinal disorders3/393/395/391/381/400/380/391/39
PruritusSkin and subcutaneous tissue disorders1/390/394/390/381/400/381/390/39
Pain in extremityMusculoskeletal and connective tissue disorders1/390/390/391/381/400/380/394/39
EcchymosisSkin and subcutaneous tissue disorders3/391/393/393/384/402/382/390/39
DizzinessNervous system disorders1/391/390/393/381/400/382/392/39
Back painMusculoskeletal and connective tissue disorders3/391/390/391/382/401/382/390/39
Abdominal pain lowerGastrointestinal disorders0/390/391/392/381/401/383/390/39
EpistaxisRespiratory, thoracic and mediastinal disorders1/390/392/391/382/400/383/392/39
Abdominal painGastrointestinal disorders0/391/390/392/382/401/383/391/39

Baseline characteristics

Age Continuous
Age Continuous(years)PPI Group 1PPI Group 2PPI Group 3PPI Group 4Total
Mean32.8 ± 6.4835.7 ± 7.9234.0 ± 7.4033.3 ± 7.1033.9 ± 7.26
Sex: Female, Male
Sex: Female, Male(Participants)PPI Group 1PPI Group 2PPI Group 3PPI Group 4Total
Female2020202080
Male2020202080
08

Study locations

1 site
  • Tempe, Arizona, United States
09

References and documents

Publications

  • Frelinger AL 3rd, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013 Feb 26;61(8):872-9. doi: 10.1016/j.jacc.2012.11.040. Epub 2013 Jan 16. PubMed 23333143 ↗
  • Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 3;59(14):1304-11. doi: 10.1016/j.jacc.2011.12.024. Erratum In: J Am Coll Cardiol. 2012 Aug 7;60(6):566-7. PubMed 22464259 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Jun 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2009
First posted
Jul 20, 2009
Start
Dec 2009
Primary completionActual
Jun 2010
CompletionActual
Jul 2010
Results first posted
Sep 7, 2011
Last update
Feb 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00942175
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 20, 2009
Start date
Dec 2009
Primary completion
Jun 2010
Completion
Jul 2010
Results posted
Sep 7, 2011
Last update
Feb 3, 2012

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clopidogrel · Lansoprazole · Dexlansoprazole · Omeprazole · Esomeprazole

Start the discussion